| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Collegium Pharmaceutical, Inc.$37.46
+0.74 (+2.02%)
B 66Pipeline Score Undervalued Pharma · Clinical
Market Cap
1.11 B
EPS
2.36
P/E Ratio
16.68 $
Value Trade
14.59 M
SEC Financials
Q1 2026Dilution Risk
Revenue
193.52 M
Operating CF
57.11 M
Total Assets
1.65 B
Total Liabilities
1.34 B
Equity
312.42 M
D/E Ratio
12,345
-2.29 %
Week
1.73 %
1 Month
-24.71 %
3 Month
-22.5 %
6 Month
38.44 %
5 Year
183.92 %
All Time
Cash Data
Cash Position
421.75 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 7, 2026
Overview
Volume
142.97 K
52 Week Range
28.74 - 50.79
% held by Insiders
2.19 %
% held by Institutions
122.85 %
Enterprise Value
1.59 B
Total Shares
32.42 M
Short %
17.23 %
Float Shares
30.41 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Collegium Pharmaceutical, Inc.
429Total events
2Upcoming
68Tier-1 (high impact)
2015 – 2027Coverage
Upcoming catalysts 2
TBD
T2Management Change
Subscribe to view catalyst details
TBD
T2Exclusivity Granted
Subscribe to view catalyst details
Event history 2
TBD
▲Exclusivity GrantedNucyntaIP / Competition
Subscribe to view catalyst details
TBD
●Oral PresentationPresentation
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2024-06-14 | Nucynta (tapentadol hydrochloride) | PDUFA Date | PDUFA | Approved | – | – | – |
2024-06-14 | Nucynta (tapentadol hydrochloride) | PDUFA Date | PDUFA | Approved | – | – | – |
2024-06-14 | Nucynta (tapentadol hydrochloride) | PDUFA Date | PDUFA | Approved | – | – | – |
Drug Pipeline Intelligence
B66
Pipeline Score $6.0B
Pipeline ValueUndervalued
Valuation Signal14
Drugs Scored15.0x
rNPV / MCap Top 93%
Micro Cap (rank 65 of 912)
Percentile RankCollegium Pharmaceutical, Inc. holds a solid B-grade pipeline (66/100), with $15.1B risk-adjusted pipeline value, led by Evolocumab in Sars-CoV-2 Infection (Phase 3), across $103B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Evolocumab Small molecule | Sars-CoV-2 Infection | Phase 3 | NCT04941105 | 56% | $7.8B | COMPLETED | 60 | - | - | May 17, 2022 | - | Apr 21, 2023 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Xtampza ER | management of pain severe enough to require daily, around-the-clock, long-term opioid treatment | — | 2017-02-01 | statistically significantly lower peak 'Drug Liking' (Emax) when compared with crushed immediate-release oxycodone; Xtampza ER when taken chewed was bioequivalent to taking it intact as determined by Cmax and AUC; statistically significant lower 'Take Drug Again' (Emax) when compared with crushed immediate-release oxycodone Read More | Collegium Announces Positive Topline Results of Human Abuse Potential Clinical Trial Evaluating the Oral Abuse of Xtampza ER Read More | |
Xtampza ER | management of pain severe enough to require daily, around-the-clock, long-term opioid treatment | — | 2017-02-01 | statistically significantly lower peak 'Drug Liking' (Emax) when compared with crushed immediate-release oxycodone; Xtampza ER when taken chewed was bioequivalent to taking it intact as determined by Cmax and AUC; statistically significant lower 'Take Drug Again' (Emax) when compared with crushed immediate-release oxycodone Read More | Collegium Announces Positive Topline Results of Human Abuse Potential Clinical Trial Evaluating the Oral Abuse of Xtampza ER Read More | |
Xtampza ER | management of pain severe enough to require daily, around-the-clock, long-term opioid treatment | — | 2017-02-01 | statistically significantly lower peak 'Drug Liking' (Emax) when compared with crushed immediate-release oxycodone; Xtampza ER when taken chewed was bioequivalent to taking it intact as determined by Cmax and AUC; statistically significant lower 'Take Drug Again' (Emax) when compared with crushed immediate-release oxycodone Read More | Collegium Announces Positive Topline Results of Human Abuse Potential Clinical Trial Evaluating the Oral Abuse of Xtampza ER Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in COLL
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
COLL Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
COLLCollegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Collegium Pharmaceutical has announced the granting of 50,305 restricted stock units (RSUs) to 34 newly hired non-executive employees as part of its 2026 Inducement Plan. This plan was adopted to comply with Nasdaq Listing Rule 5635(c)(4) and aims to enhance employee retention through a structured vesting schedule. The RSUs will vest over a three-year period, contingent on continued employment.
Read more →COLLCollegium to Participate in 2026 Jefferies Global Healthcare Conference
Collegium Pharmaceutical, Inc. will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 3, 2026. The event will be available via a live webcast on the company's website, with a replay accessible for 90 days. Collegium focuses on innovative treatments for central nervous system and pain conditions.
Read more →COLLCollegium Completes Acquisition of AZSTARYS from Corium Therapeutics - Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium's Existing ADHD Portfolio - - Extends Collegium'
Collegium Pharmaceutical has successfully acquired AZSTARYS from Corium Therapeutics, a CNS stimulant targeted for ADHD treatment. This acquisition is expected to complement Collegium's existing ADHD portfolio and enhances its financial outlook, projecting 2026 product revenues to reach between $865 and $895 million. Additionally, the company anticipates significant operational synergies and immediate revenue accretion. Collegium aims to integrate AZSTARYS into its commercial infrastructure effectively, thereby expanding treatment options available to patients and prescribers.
Read more →COLL▲ +7.7%on this newsshared move
Collegium Reports First Quarter 2026 Financial Results and Highlights Recent Company Progress
Collegium Pharmaceutical, Inc. reported its financial results for Q1 2026, highlighting a 9% year-over-year increase in net revenues to $193.5 million. The company saw significant growth in its JORNAY PM product, with net revenues rising 36%, attributed to an increase in prescriptions and new prescribers. Collegium is on track to finalize its acquisition of AZSTARYS in Q2 2026, which is expected to bolster its ADHD portfolio further. The company remains committed to its strategic priorities and has reaffirmed its financial guidance for the year.
Read more →COLLCollegium to Report First Quarter 2026 Financial Results on May 7, 2026
Collegium Pharmaceutical, Inc. announced it will report its first quarter 2026 financial results on May 7, 2026, before market opening. Following the announcement, a live conference call and webcast will be held at 8:00 a.m. ET. The company is focused on enhancing its portfolio, particularly with its ADHD treatment, JORNAY PM.
Read more →COLLCollegium to Participate in Upcoming Investor Conferences
Collegium Pharmaceutical, Inc. has announced its participation in two upcoming investor conferences, including the 25th Annual Needham Virtual Healthcare Conference and the Piper Sandler Spring Biopharma Symposium. The fireside chat at the Needham conference will take place on April 15, 2026, at 2:15 p.m. ET, with a live webcast available on the company's website. Collegium continues to focus on expanding its portfolio, particularly in responsible pain management and ADHD treatment.
Read more →COLLCollegium to Acquire AZSTARYS from Corium Therapeutics, Strengthening Position in ADHD and Accelerating Growth Trajectory - Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Colle
Collegium Pharmaceutical announced its acquisition of AZSTARYS from Corium Therapeutics for $650 million, expected to close in Q2 2026, pending regulatory approvals. This strategic acquisition aims to strengthen Collegium's existing ADHD portfolio, with AZSTARYS projected to generate significant revenue and boast strong patent protection. CEO Vikram Karnani highlighted this move as key to accelerating growth and enhancing patient care. The deal also includes potential milestone payments of up to $135 million, further emphasizing its strategic importance.
Read more →COLL▼ -5.9%on this news
Collegium to Present New Real-World Data at PainConnect 2026
Collegium Pharmaceutical, Inc. will present two posters featuring real-world data from its pain medication portfolio at PainConnect 2026. This event, hosted by the American Academy of Pain Medicine, will take place in Salt Lake City from March 5-8, 2026. The presentations aim to provide valuable insights into pain management practices.
Read more →COLLParis Hilton Shares Her Experience with JORNAY PM and Launches New 'Embrace Your Sparkle' Campaign with Collegium to Empower the ADHD Community
Collegium Pharmaceutical and Paris Hilton have launched the 'Embrace Your Sparkle' campaign to raise awareness about ADHD. The initiative aims to challenge stereotypes and promote open dialogue about the condition. Hilton shares her personal experiences with ADHD and emphasizes the importance of individualized treatment plans, highlighting her use of JORNAY PM for symptom management.
Read more →COLLCollegium Reports Fourth Quarter and Full-Year 2025 Financial Results
Collegium Pharmaceutical reported strong financial results for Q4 and full-year 2025, with net revenues reaching $205.4 million for the quarter and $780.6 million for the year. The company's Jornay PM product saw significant growth, contributing to a 48% increase in full-year revenue. Collegium's pain portfolio also performed well, and the company reaffirmed its guidance for 2026, indicating a positive outlook for continued growth.
Read more →COLLCollegium to Report Fourth Quarter and Full-Year 2025 Financial Results on February 26, 2026
Collegium Pharmaceutical, Inc. will report its fourth quarter and full-year 2025 financial results on February 26, 2026. The announcement includes details about a live conference call and webcast scheduled for 8:00 a.m. ET on the same day. The company aims to enhance its portfolio, focusing on pain management and ADHD treatments.
Read more →COLLCollegium to Present Four Real-World Data Posters at APSARD 2026 Annual Conference
Collegium Pharmaceutical announced it will present four posters featuring real-world data on its ADHD treatment, Jornay PM, at the APSARD Annual Conference in San Diego. The presentations aim to provide valuable insights for clinicians and the ADHD community. The conference will take place from January 15-18, 2026, with the poster session scheduled for January 17.
Read more →COLLCollegium Provides 2026 Financial Guidance and Business Update - Product Revenues, Net Expected in the Range of $805 Million to $825 Million - - Jornay PM Net Revenue Expected in the Range of $190 Million to $200 Million
Collegium Pharmaceutical, Inc. announced its financial guidance for 2026, projecting product revenues between $805 million and $825 million. The company expects net revenue from Jornay PM to range from $190 million to $200 million, reflecting continued strong demand. Collegium expresses confidence in its capital deployment strategy, focusing on debt reduction and share repurchases while expanding its portfolio. This positive outlook follows a record growth year in 2025, as stated by the company's executives.
Read more →COLLCollegium Announces the Closing of $980 Million Syndicated Credit Facility
Collegium Pharmaceutical has successfully closed a $980 million syndicated credit facility, which includes a $580 million initial term loan and additional funding options. This facility is expected to enhance the company's financial outlook and provide flexibility for future business development. The initial loan will pay off a previous term loan, resulting in significant interest savings.
Read more →COLL▲ +13.4%on this news· ran to +25% by day 3
Collegium Reports Third Quarter 2025 Financial Results; Raises 2025 Guidance
Collegium Pharmaceutical reported strong financial results for Q3 2025, achieving record net revenue of $209.4 million, a 31% increase from the previous year. The company's Jornay PM product saw significant growth, contributing to the overall revenue increase. Additionally, Collegium raised its full-year guidance for net revenue to between $775 and $785 million, reflecting confidence in continued growth.
Read more →COLLParis Hilton Collaborates with Collegium Pharmaceutical to Share Her Personal ADHD Journey and Experience with Treatment
Collegium Pharmaceutical collaborates with Paris Hilton to share her ADHD journey, aiming to reduce stigma and encourage others to seek treatment. Hilton discusses her diagnosis and treatment with JORNAY PM, a CNS stimulant. The initiative highlights the importance of awareness during ADHD Awareness Month.
Read more →COLLCollegium to Report Third Quarter 2025 Financial Results on November 6, 2025
Collegium Pharmaceutical, Inc. will report its third quarter 2025 financial results on November 6, 2025, before market opening. Following the release, a live conference call and webcast will occur at 8:00 a.m. ET. The company aims to enhance its portfolio, focusing on responsible pain management and ADHD treatments.
Read more →COLLCollegium Announces Poster Presentations at the American Academy of Child & Adolescent Psychiatry and Neuroscience Education Institute Conferences
Collegium Pharmaceutical announced poster presentations at the AACAP and NEI conferences, showcasing real-world data on Jornay PM, a CNS stimulant for ADHD. The presentations aim to provide insights into Jornay PM's use and reinforce the company's commitment to improving ADHD care. The conferences will take place in Chicago and Colorado Springs later this year.
Read more →COLLCollegium to Celebrate 10-Year Anniversary with Nasdaq Opening Bell Ringing
Collegium Pharmaceutical, Inc. will celebrate its 10-year anniversary on October 14, 2025, by ringing the Nasdaq opening bell. The company has made significant strides in responsible pain management and has expanded into neuropsychiatry with the acquisition of Jornay PM for ADHD. This milestone highlights their commitment to improving patient lives and their growth trajectory in the healthcare sector.
Read more →COLLCollegium to Present Nine Real-World Data Posters at PAINWeek 2025 Annual Meeting
Collegium Pharmaceutical, Inc. will showcase nine posters featuring real-world data from its pain management portfolio at PAINWeek 2025 in Las Vegas. The presentations aim to enhance clinical decision-making by providing healthcare professionals with valuable insights. This initiative reflects Collegium's ongoing commitment to responsible pain management.
Read more →COLL▲ +10.7%on this news· ran to +27% by day 3
Collegium Reports Second Quarter 2025 Financial Results; Raises 2025 Outlook
Collegium Pharmaceutical reported a strong second quarter for 2025, achieving record net revenue of $188 million, a 29% increase year-over-year. The company also raised its full-year revenue guidance to between $745 and $760 million, driven by robust sales from its pain portfolio and Jornay PM. The CEO expressed optimism for continued growth in the second half of the year.
Read more →COLLCollegium to Report Second Quarter 2025 Financial Results on August 7, 2025
Collegium Pharmaceutical, Inc. has announced its schedule to report second quarter 2025 financial results before the market opens on August 7, 2025. Following the financial release, there will be a live conference call and webcast at 8:00 a.m. ET. The company has a diversified portfolio in pain management and recently expanded into neuropsychiatry with the acquisition of Jornay PM. They are focused on disciplined capital deployment and growing their commercial offerings.
Read more →COLLCollegium Announces $150 Million Share Repurchase Program
Collegium Pharmaceutical, Inc. has announced a new share repurchase program worth $150 million, set to run through December 31, 2026. This program replaces a previous one that had $65 million remaining when it expired. The company's commitment to returning value to shareholders is emphasized by its history of returning $222 million since 2021 and confidence in its growth trajectory, particularly in its key product segments. The firm continues to focus on disciplined capital allocation and reducing debt while supporting shareholder value through stock repurchases.
Read more →COLLCollegium Announces $25 Million Accelerated Share Repurchase Program
Collegium Pharmaceutical announced an Accelerated Share Repurchase (ASR) program of $25 million in collaboration with Jefferies LLC. This initiative is part of a broader $150 million share repurchase program approved by the company's Board of Directors. The ASR is expected to strengthen capital allocation while enhancing shareholder returns, coinciding with a reported 23% increase in revenues for the first quarter compared to the previous year. Following the ASR's completion, Collegium will retain $65 million remaining under the repurchase program, reinforcing its commitment to future growth.
Read more →COLLCollegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress - Generated Q1'25 Quarterly Net Revenue of $177.8 Million, Up 23% Year-over-Year - - Grew Jornay PM Prescriptions by 24% Year-
Collegium Pharmaceutical reported robust financial results for Q1 2025, with a 23% increase in quarterly net revenue reaching $177.8 million. Key growth driver Jornay PM saw a 24% rise in prescriptions, and the company expanded its sales force significantly. Collegium also reaffirmed its full-year 2025 guidance, indicating strong confidence in its continued financial performance. The quarter ended with a commendable cash position of $197.8 million and a new accelerated share repurchase program authorized by the board.
Read more →COLLCollegium to Report First Quarter 2025 Financial Results on May 8, 2025
Collegium Pharmaceutical, Inc. will report its first quarter 2025 financial results on May 8, 2025, after the market closes. The company will also host a live conference call and webcast at 4:30 p.m. ET on the same day. Collegium focuses on building a diversified biopharmaceutical company with a strong emphasis on pain management and neuropsychiatry following its recent acquisition of Jornay PM. Investors can access the conference call via a provided phone number or through the company's website.
Read more →COLLCollegium to Participate in 24th Annual Needham Virtual Healthcare Conference
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced its participation in the 24th Annual Needham Healthcare Conference, scheduled for April 7-10, 2025. The company will engage in a fireside chat on April 8, 2025, at 9:30 a.m. ET, which will be available for live viewing on their website. Collegium aims to boost its portfolio, focusing on responsible pain management and ADHD treatment with Jornay PM.
Read more →COLLCollegium to Present Real-World Data at PainConnect 2025, the American Academy of Pain Medicine’s Annual Meeting
Collegium Pharmaceutical, Inc. announced its participation in PainConnect 2025 where it will present four posters showcasing real-world patient data from its pain portfolio. One poster, which discusses the clinical outcomes associated with buprenorphine pain medications, has been distinguished as a top abstract by the American Academy of Pain Medicine. The meeting will take place in Austin, TX from April 3-6, 2025, with presentations scheduled for April 4. Collegium aims to highlight its commitment to responsible pain management through this event.
Read more →COLLCollegium Announces Updates to its Board of Directors and Executive Leadership Team
Collegium Pharmaceutical, Inc. has announced significant changes to its Board of Directors and executive leadership team as part of its strategic focus on growth. Founder Michael Heffernan and Board Member Gwen A. Melincoff will retire, with Gino Santini stepping in as Chairman of the Board. Additionally, Dr. Carlos Paya is nominated for board membership, while David Dieter, Jane Gonnerman, and Dean J. Patras have been appointed as new executives, enhancing the company’s leadership team to support its strategic goals, including the expansion of its pain management and ADHD treatment portfolios.
Read more →COLLCollegium Announces Poster Presentations at the 2025 National Association of Pediatric Nurse Practitioners National Conference on Pediatric Health Care
Collegium Pharmaceutical, Inc. announced two poster presentations at the 2025 National Association of Pediatric Nurse Practitioners National Conference in Chicago. The presentations will showcase real-world data related to Jornay PM, a treatment for attention deficit hyperactivity disorder (ADHD). This highlights Collegium's commitment to providing innovative therapeutic options for the ADHD community, underlining the importance of Jornay PM as an effective choice for managing ADHD symptoms.
Read more →COLLCollegium Reports Record Fourth Quarter and Full-Year 2024 Financial Results - Generated Record Quarterly and Full-Year Net Revenue of $181.9 Million and $631.4 Million - - Reported Quarterly Jornay PM Net Revenue of $29
Collegium Pharmaceutical, Inc. (COLL) reported impressive financial results for the fourth quarter and full year of 2024, with record net revenues of $181.9 million and $631.4 million, respectively. The company reported a GAAP net income of $12.5 million and a full-year adjusted EBITDA of $401.2 million. Collegium reaffirmed its financial guidance for 2025, expecting product revenues in the range of $735 million to $750 million, a notable increase from the previous year. The company highlighted its strategic focus on growing its pain management portfolio and maximizing the potential of its recently acquired product, Jornay PM.
Read more →COLLCollegium to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025
Collegium Pharmaceutical, Inc. will report its fourth quarter and full-year 2024 financial results on February 27, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. ET to discuss these results. Collegium is focused on providing treatments for serious medical conditions, including responsible pain management medications and ADHD with the recent acquisition of Jornay PM.
Read more →COLLCollegium Appoints Nancy S. Lurker to its Board of Directors
Collegium Pharmaceutical, Inc. has announced the appointment of Nancy S. Lurker to its Board of Directors, effective February 4, 2025. Lurker's experience is expected to enhance Collegium's commercial growth and strategic acquisitions, particularly following the company's recent expansion into the neuropsychiatry market. She has previously held significant positions at various biopharmaceutical companies, providing her with a strong background to contribute to Collegium's mission. The appointment reflects Collegium's commitment to building a diversified biopharmaceutical company focused on improving lives.
Read more →COLL▲ +14.4%on this news
Collegium Provides 2025 Financial Guidance and Business Update - Product Revenues, Net Expected in the Range of $735 Million to $750 Million - - Jornay PM Net Revenue Expected to be in Excess of $135 Million - - Adjusted
Collegium Pharmaceutical, Inc. announced its financial guidance for 2025, projecting product revenues between $735 million to $750 million. The estimated net revenue for Jornay PM, the company's ADHD treatment, is expected to surpass $135 million. Collegium's President and CEO highlighted a commitment to capitalizing on their pain management portfolio while emphasizing growth through strategic investments. The company completed the integration of Ironshore Therapeutics and remains focused on delivering strong performance and shareholder value.
Read more →COLLCollegium Reports Record Third Quarter 2024 Financial Results - Generated Record Q3'24 Net Revenue of $159.3 Million, Up 17% Year-over-Year, Driven by Record Belbuca Revenue of $53.2 Million and Record Xtampza ER Revenue
Collegium Pharmaceutical reported strong financial results for Q3 2024, generating record net revenue of $159.3 million, an increase of 17% compared to the previous year. The growth was driven primarily by record revenue from Belbuca and Xtampza ER, which reached $53.2 million and $49.5 million, respectively. Additionally, the company has successfully closed its acquisition of Ironshore Therapeutics, enhancing its portfolio into neurology. The appointment of Vikram Karnani as the new CEO positions Collegium for further growth in the pharmaceutical market.
Read more →COLLCollegium Appoints Vikram Karnani as Chief Executive Officer
Collegium Pharmaceutical, Inc. has announced the appointment of Vikram Karnani as its new Chief Executive Officer and President, effective November 12, 2024. Karnani, who has over 15 years of experience in the life sciences industry, previously held executive roles at Horizon Therapeutics and Amgen. His appointment comes at a time when Collegium is experiencing strong revenue growth from its pain management portfolio and is expanding into neurology. The company's chairman expressed confidence in Karnani's ability to lead Collegium through its next phase of growth.
Read more →COLLCollegium to Report Third Quarter 2024 Financial Results on November 7, 2024
Collegium Pharmaceutical, Inc. has announced that it will report its third quarter 2024 financial results on November 7, 2024, after market close. Following the financial release, the company will host a live conference call and webcast at 4:30 p.m. ET to discuss the results. Collegium, based in Stoughton, Massachusetts, emphasizes its commitment to improving the lives of people with serious medical conditions. Interested parties can access the webcast on the company’s website, with a replay available shortly after the event.
Read more →COLLCollegium Completes Acquisition of Ironshore Therapeutics - Adds Commercial Product Jornay PM , Establishing Collegium's Presence in Neurology (ADHD) - - Collegium Updates 2024 Financial Guidance to Reflect Expected Imme
Collegium Pharmaceutical has successfully completed the acquisition of Ironshore Therapeutics, integrating its ADHD treatment Jornay PM into its product portfolio. This acquisition is viewed as a strategic move to establish Collegium's presence in the neurology market, particularly in the growing ADHD sector. Financial guidance for 2024 has been updated to reflect anticipated revenues of $620 to $635 million due to the integration of Jornay PM, which is projected to generate over $100 million in net revenue. However, the financing of the acquisition through a significant loan introduces increased debt risk, and Jornay PM's potential for abuse presents safety concerns.
Read more →COLLCollegium to Participate in H.C. Wainwright 26th Annual Global Investment Conference
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference scheduled for September 9-11, 2024, in New York, NY. The management will engage in a fireside chat on September 9 at 12:30 p.m. ET, which will be accessible via a live webcast on the company's website. A replay of the webcast will be available for 90 days following the event, underlining the company's commitment to transparency with investors.
Read more →COLLCollegium Announces Eight Poster Presentations at PAINWeek Conference 2024
Collegium Pharmaceutical, Inc. announced it will present eight posters at the upcoming PAINWeek Conference 2024, showcasing data from its pain management portfolio. The presentations aim to highlight the clinical and population health impact of its therapies, including insights derived from real-world patient data. Chief Medical Officer Thomas Smith emphasized the importance of sharing this data with healthcare decision-makers to advance responsible pain management practices. The conference will take place in Las Vegas from September 3 to 6, 2024.
Read more →COLLCollegium Reports Second Quarter 2024 Financial Results - Generated Q2'24 Net Revenue of $145.3 Million and Record Belbuca Revenue of $52.2 Million, Up 7% and 21% Year-over-Year, Respectively - - Achieved Q2'24 GAAP Net
Collegium Pharmaceutical, Inc. reported strong financial results for Q2 2024, with net revenue reaching $145.3 million and record Belbuca revenue of $52.2 million. The company achieved a GAAP net income of $19.6 million, reflecting a 51% year-over-year increase. Collegium also plans to finalize the acquisition of Ironshore Therapeutics, which will allow it to enter the ADHD market with the product Jornay PM. Financial guidance for full-year 2024 has been reaffirmed despite the upcoming acquisition.
Read more →COLLCollegium to Acquire Ironshore Therapeutics, Expanding into Neurology - Adds Commercial Product Jornay PM , Establishing Collegium's Presence in Neurology (ADHD) - - H1'24 Jornay PM Prescriptions Grew 32% Year-over-Year
Collegium Pharmaceutical has announced the acquisition of Ironshore Therapeutics for $525 million, aimed at expanding into neurology with Jornay PM, a treatment for ADHD. The deal is expected to close in Q3 2024 and should be immediately beneficial to Collegium's financials. Jornay PM has seen a significant increase in prescriptions, reflecting strong demand. The acquisition aligns with Collegium's strategy to diversify its offerings beyond pain management.
Read more →COLLCollegium to Report Second Quarter 2024 Financial Results on August 8, 2024
Collegium Pharmaceutical, Inc. has announced that it will report its second quarter 2024 financial results on August 8, 2024, after market closure. Following the financial announcement, a live conference call will take place at 4:30 p.m. ET, which will also be available for replay. The company emphasizes its commitment to enhancing lives of those with serious medical conditions.
Read more →COLLCollegium Obtains Six Month Extension of U.S. Pediatric Exclusivity for Nucynta Franchise
Collegium Pharmaceutical, Inc. has announced a six-month extension of pediatric exclusivity for its Nucynta franchise, now extending the exclusivity period to January 3, 2027, for Nucynta and December 27, 2025, for Nucynta ER. This decision was granted by the U.S. Food and Drug Administration (FDA) and enhances the franchise's market value. The exclusivity primarily supports the management of acute pain in pediatric patients, underscoring Collegium's commitment to addressing serious medical conditions through its products.
Read more →COLLCollegium to Participate in Jefferies Global Healthcare Conference
Collegium Pharmaceutical, Inc. will participate in the Jefferies Global Healthcare Conference in New York on June 5-6, 2024. The event will feature a fireside chat with company management, which will be available for live streaming. This participation emphasizes Collegium's ongoing commitment to serious medical conditions and positions the company within the healthcare industry.
Read more →COLLCollegium Announces $35 Million Accelerated Share Repurchase Program
Collegium Pharmaceutical, Inc. announced a $35 million Accelerated Share Repurchase agreement with Jefferies LLC as part of a larger $150 million share repurchase initiative. The company aims to utilize this agreement to bolster shareholder value, citing strong financial performance in 2024 and promising outcomes for its product lines. Following the completion of this repurchase, Collegium anticipates having $115 million remaining in its authorized program. This strategy underscores the company's confidence in its stock valuation and future growth outlook.
Read more →COLLCollegium Announces CEO Transition
Collegium Pharmaceutical, Inc. announced the resignation of CEO Joe Ciaffoni, effective May 24, 2024. Michael Heffernan, the company's founder and former CEO, will serve as Interim President and CEO while the Board of Directors seeks a new CEO. Ciaffoni will remain on the Board until the 2024 Annual Meeting of Shareholders. The company emphasized its financial strength and strong leadership as it prepares for future growth.
Read more →COLLCollegium Reports First Quarter 2024 Financial Results - Generated Q1'24 Net Revenue of $144.9 Million - - Delivered Q1'24 Record Belbuca Revenue of $50.7 Million; Total Prescriptions Up 4.2% Year-over-Year - - Achieved
Collegium Pharmaceutical, Inc. reported strong financial results for the first quarter of 2024, achieving a net revenue of $144.9 million and record Belbuca revenue of $50.7 million. The company shifted from a net loss in the previous year to a net income of $27.7 million. Collegium has also announced a $35 million accelerated share repurchase program to enhance shareholder value and reaffirmed its full-year guidance for 2024, indicating optimism about future performance and growth.
Read more →COLLCollegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta and Nucynta ER
Collegium Pharmaceutical, Inc. has announced an authorized generic agreement with Hikma Pharmaceuticals USA Inc. to sell authorized generic versions of its products Nucynta and Nucynta ER in the United States. Under this agreement, Collegium will manufacture the products while Hikma will handle sales, beginning 30 days prior to the anticipated loss of exclusivity. This collaboration is expected to add value to the Nucynta Franchise through 2025, allowing Collegium to benefit from net profits of these generics, which may fluctuate based on competition in the market.
Read more →COLLCollegium to Report First Quarter 2024 Financial Results on May 9, 2024
Collegium Pharmaceutical, Inc. announced it will report its first quarter 2024 financial results on May 9, 2024, after market close. Following the release, the company will host a live conference call and webcast to discuss the results. The call will begin at 4:30 p.m. ET. Collegium aims to update stakeholders on its performance and continues its commitment to addressing serious medical conditions.
Read more →COLLCollegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026
Collegium Pharmaceutical, Inc. has announced the redemption of its outstanding 2.625% Convertible Senior Notes due 2026, totaling $26,350,000 in principal. The redemption is set for June 14, 2024, and arises because the company's common stock exceeded 130% of the conversion price. Holders of the notes can convert their holdings to common shares prior to the redemption deadline. This move showcases the company's financial health and confidence in its market position.
Read more →COLLCollegium to Participate in 23rd Annual Needham Virtual Healthcare Conference
Collegium Pharmaceutical, Inc. announced its participation in the 23rd Annual Needham Healthcare Conference, which will take place virtually from April 8-11, 2024. The company will engage in a fireside chat scheduled for April 10, 2024, at 3:45 p.m. ET, which will be webcast live. The event underscores Collegium's mission of improving the lives of individuals with serious medical conditions. A replay of the webcast will be available on the company's website for 90 days post-presentation.
Read more →COLLCollegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results - Generated Record Quarterly and Full-Year Net Revenue of $149.7 Million and $566.8 Million - - Achieved Quarterly and Full-Year GAAP Net Incom
Collegium Pharmaceutical reported impressive financial results for the fourth quarter and full-year 2023, with record revenues of $149.7 million and $566.8 million respectively. The company also highlighted record adjusted EBITDA of $367 million and a strong cash position at the end of the year. Key strategies for 2024 include focusing on operational execution and leveraging product growth from Belbuca and Xtampza ER. Collegium aims to continue delivering value to shareholders while managing its financial obligations.
Read more →COLLCollegium to Report Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
Collegium Pharmaceutical, Inc. announced that it will report its fourth quarter and full-year 2023 financial results on February 22, 2024. Following the release, the company will hold a live conference call and webcast to discuss the details. This event illustrates Collegium's commitment to communication with stakeholders and provides an opportunity for investors to gain insights into the company's performance.
Read more →COLL▲ +8.4%on this news
Collegium Provides 2024 Financial Guidance
Collegium Pharmaceutical, Inc. has announced its financial guidance for 2024, with product revenues anticipated between $580 million and $595 million and adjusted EBITDA projected at $380 million to $395 million. The company reported strong performance in 2023, attributing a 20% revenue growth and a 35% jump in adjusted EBITDA to the sales of Belbuca and Xtampza ER. Collegium's board has also authorized a new $150 million share repurchase program, underscoring its commitment to returning value to shareholders. The company is focusing on operational execution to achieve its financial commitments going forward.
Read more →COLL▲ +8.4%on this news
Collegium Provides 2024 Financial Guidance - Product Revenues, Net Expected in the Range of $580.0 Million to $595.0 Million - - Adjusted Operating Expenses* Expected in the Range of $120.0 Million to $125.0 Million - -
Collegium Pharmaceutical, Inc. has provided its financial guidance for 2024, projecting product revenues between $580 million and $595 million and adjusted EBITDA of $380 million to $395 million. The company reported substantial growth in 2023, attributing success to their products Belbuca and Xtampza ER. Additionally, a new $150 million share repurchase program has been authorized to enhance shareholder value. Collegium's management emphasizes continued focus on operational execution and effective capital deployment for upcoming years.
Read more →COLLCollegium Reports Third Quarter 2023 Financial Results - Q3'23 Net Revenue of $136.7 Million, Up 8% Year-over-Year - - Q3'23 GAAP Net Income of $20.6 Million vs. Q3'22 GAAP Net Income of $0.5 Million - - Record Q3'23 Adj
Collegium Pharmaceutical, Inc. reported strong financial results for Q3 2023, with net revenue of $136.7 million, an increase of 8% year-over-year, and a significant rise in GAAP net income to $20.6 million. The company also achieved record adjusted EBITDA of $89.4 million, reflecting a 19% year-over-year growth. Additionally, Collegium announced a $25 million accelerated share repurchase program and extended the regulatory exclusivity for Nucynta through July 2026, bolstering its growth outlook. Management expressed confidence in delivering substantial revenue growth for the full year 2023.
Read more →COLLCollegium to Report Third Quarter 2023 Financial Results on November 7, 2023
Collegium Pharmaceutical, Inc. has announced that it will report its financial results for the third quarter of 2023 on November 7, 2023. The report will be released after market close, followed by a live conference call at 4:30 p.m. ET. This event provides an opportunity for investors to engage with the company and learn more about its financial performance and strategic goals.
Read more →COLLCollegium Announces 10 Poster Presentations at PAINWeek Conference 2023
Collegium Pharmaceutical, Inc. announced that it will present 10 poster presentations at the PAINWeek Conference 2023, scheduled for September 5-8 in Las Vegas, NV. These presentations will highlight data related to its pain portfolio, emphasizing the clinical and population health impact of their products. The Chief Medical Officer expressed pride in sharing new real-world data to benefit healthcare providers treating pain patients. The posters will be accessible on the conference website on September 6-7, 2023.
Read more →COLLCollegium Announces Extension of Nucynta Regulatory Exclusivity through July 2026
Collegium Pharmaceutical announced that the FDA has granted New Patient Population exclusivity for its product Nucynta, extending its regulatory exclusivity to July 3, 2026. This decision is based on data from pediatric trials aimed at assessing Nucynta's use in children aged 6 and older. The company intends to further pursue a pediatric extension that could prolong exclusivity for the entire Nucynta franchise into late 2025 and early 2027. Collegium expresses its commitment to enhancing treatment options for acute severe pain with Nucynta.
Read more →COLLCollegium Announces $50 Million Accelerated Share Repurchase Program
Collegium Pharmaceutical, Inc. announced a $50 million accelerated share repurchase program as part of its $100 million stock buyback authorized earlier this year. This move reflects the company's confidence in its financial stability and business strategy. Approximately 1.7 million shares will be repurchased initially, with the final number subject to market price adjustments. The ASR is expected to be completed in the fourth quarter of 2023, marking a significant step in Collegium's efforts to enhance shareholder value.
Read more →COLLCollegium Reports Record 1H'23 Net Revenue of $280.3 Million, Up 35% Year-over-Year - Q2'23 Net Revenue of $135.5 Million, Up 10% Year-over-Year - - Q2'23 GAAP Net Income of $13.0 Million - - Q2'23 Adjusted EBITDA of $85
Collegium Pharmaceutical, Inc. reported a record net revenue of $280.3 million for the first half of 2023, marking a 35% year-over-year increase. The company also recorded Q2'23 net revenue of $135.5 million, up by 10%, along with a GAAP net income of $13 million and adjusted EBITDA of $85.8 million, up 21%. Furthermore, the board has authorized a $50 million accelerated share repurchase program, expressing confidence in the company’s direction. The organization reaffirmed its full-year guidance for 2023, aiming to continue its revenue growth and effective expense management.
Read more →COLLCollegium to Report Second Quarter 2023 Financial Results on August 3, 2023
Collegium Pharmaceutical, Inc. will announce its financial results for the second quarter of 2023 on August 3, 2023, after market close. The company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss these results. This announcement reflects Collegium’s commitment to transparency and communication with its investors.
Read more →COLLCollegium to Participate in Jefferies Healthcare Conference
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) will be participating in a fireside chat at the Jefferies Healthcare Conference in New York from June 7-9, 2023. The chat is scheduled for June 8, 2023, at 12:30 p.m. ET and will be webcast live, with an archived version available for 90 days post-event. This event indicates Collegium's ongoing commitment to engage with the investment community and foster transparency regarding its operations and initiatives.
Read more →COLLCollegium Reports First Quarter 2023 Financial Results - Generated Record Net Revenue of $144.8 Million - - Delivered Record Belbuca and Xtampza ER Net Revenue - - Ended Q1'23 with Cash Balance of $269.5 Million - - Reaf
Collegium Pharmaceutical reported a record net revenue of $144.8 million for Q1 2023, driven by strong sales of Belbuca and Xtampza ER. The company ended the quarter with a solid cash balance of $269.5 million and reaffirmed its revenue guidance for the full year. Executives expressed confidence in achieving strategic and financial goals for 2023, showcasing financial strength and discipline. The management is focused on exploring business development opportunities to enhance shareholder value.
Read more →COLLCollegium to Report First Quarter 2023 Financial Results on May 4, 2023
Collegium Pharmaceutical, Inc. announced it will report its first quarter 2023 financial results on May 4, 2023, after market close. The company will follow up with a live conference call at 4:30 p.m. ET to discuss these results. Investors can access the call via phone or through an audio webcast on Collegium's website, with replays available shortly after the event.
Read more →COLLCollegium to Participate in 22nd Annual Needham Virtual Healthcare Conference
Collegium Pharmaceutical, Inc. has announced its participation in the 22nd Annual Needham Virtual Healthcare Conference. The event will feature a fireside chat scheduled for April 18, 2023, at 2:15 p.m. ET. This opportunity allows Collegium to engage with investors and highlight its dedication to improving the lives of individuals with serious medical conditions. The fireside chat will be streamed live, with a replay available for 90 days afterward.
Read more →COLLCollegium Reports Fourth Quarter and Full-Year 2022 Financial Results - Generated Record Quarterly and Full-Year Net Revenue of $129.6 and $463.9 Million - - Ended 2022 with Cash Balance of $173.7 Million - - Reaffirmed
Collegium Pharmaceutical, Inc. reported record financial results for Q4 and full-year 2022, with net revenues of $129.6 million and $463.9 million, respectively. The company ended the year with a cash balance of $173.7 million and reaffirmed optimistic financial guidance for 2023. Key achievements included the successful integration of BDSI, significant risk mitigation by resolving opioid lawsuits, and a focus on returning capital to shareholders. The leadership expressed confidence that 2023 would be a landmark year for overall growth.
Read more →COLLCollegium Publishes Inaugural 2022 Environmental, Social and Governance Report
Collegium Pharmaceutical, Inc. has released its first Environmental, Social and Governance (ESG) report, outlining its commitment to ethical practices, corporate governance, and community engagement. The report highlights various initiatives, including diversity and equity plans, employee culture surveys, and significant donations towards STEM education. CEO Joe Ciaffoni emphasized the importance of these efforts for corporate accountability and plans for continued growth in 2023. The report reflects Collegium's dedication to operating responsibly while maximizing shareholder value.
Read more →COLLCollegium Pharmaceutical, Inc. Prices Upsized $210.0 Million Convertible Senior Notes Offering
Collegium Pharmaceutical, Inc. announced the successful pricing of an upsized offering of $210 million in convertible senior notes due 2029. The offering was increased from an initial target of $175 million and is expected to settle on February 10, 2023. The company plans to use a significant portion of the proceeds to repurchase existing convertible notes due in 2026, along with other general corporate purposes. This move is seen as a strategic step to enhance its financial position, though potential risks related to market conditions are acknowledged.
Read more →COLLCollegium Pharmaceutical, Inc. Announces Proposed Convertible Senior Notes Offering
Collegium Pharmaceutical, Inc. has announced its intent to offer $175 million in convertible senior notes due 2029 in a private offering to qualified institutional buyers. The notes will be unsecured obligations, accruing interest payable semi-annually, and will be redeemable by Collegium under certain conditions. The company plans to utilize part of the proceeds to repurchase existing convertible senior notes due 2026, with the remainder intended for general corporate purposes. The offering is subject to market conditions and other factors, and it aims to strengthen Collegium's financial position.
Read more →COLLCollegium Announces Fourth Quarter and Full Year 2022 Preliminary Financial Results -Results at or above high-end of 2022 earnings guidance- -Final fourth quarter and full year 2022 financial results to be announced afte
Collegium Pharmaceutical has announced preliminary, unaudited financial results for the fourth quarter and full year of 2022, indicating revenues at or above the high-end of its earnings guidance. The company will provide detailed financial results on February 23, 2023, following the close of the market. Estimated GAAP operating expenses for the fourth quarter are projected to range from $38.4 million to $43.4 million, while full year expenses are expected between $176.5 million and $181.5 million. These results are subject to change pending a final audit review.
Read more →COLL▲ +14.4%on this news
Collegium Provides 2023 Financial Guidance
Collegium Pharmaceutical, Inc. has announced its financial guidance for 2023, projecting product revenues between $565 million to $580 million and adjusted EBITDA ranging from $355 million to $370 million. The company highlights a new $100 million share repurchase program and anticipates significant revenue growth driven by its products Xtampza ER and Belbuca. Successful integration of BDSI and favorable patent rulings contribute to a positive outlook as Collegium aims to strengthen its market position in responsible pain management.
Read more →COLL▲ +14.4%on this news
Collegium Provides 2023 Financial Guidance - Product Revenues, Net Expected in the Range of $565.0 Million to $580.0 Million - - Adjusted Operating Expenses* Expected in the Range of $135.0 Million to $145.0 Million - -
Collegium Pharmaceutical, Inc. has announced its financial guidance for 2023, projecting net product revenues between $565 million and $580 million. The company's adjusted operating expenses are expected to range from $135 million to $145 million. CEO Joe Ciaffoni expressed confidence that 2023 will be a pivotal year, citing accomplishments such as contract renegotiations and growth momentum in their pain management portfolio. Additionally, a $100 million share repurchase program has been authorized to enhance shareholder value.
Read more →COLLAppeals Court Affirms Validity of Collegium's Belbuca Patents - Ruling bars ANDA filer Alvogen from entering market until 2032 patent expiry
Court Affirms Validity of Collegium's Belbuca Patents - Ruling bars ANDA filer Alvogen from entering market until 2032 patent expiry - Mass., December 22, 2022 -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today ann
Read more →COLLCollegium to Participate in Piper Sandler 34th Annual Healthcare Conference
STOUGHTON, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that management will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference b
Read more →COLLCollegium Reports Third Quarter 2022 Financial Results - Generated Record Net Revenue of $127.0 Million - - Completed Xtampza ER Contract Renegotiations, Confirmed Xtampza ER Gross-To-Net Will be Less Than 65% Beginning
Collegium Reports Third Quarter 2022 Financial Results - Generated Record Net Revenue of $127.0 Million - - Completed Xtampza ER Contract Renegotiations, Confirmed Xtampza ER Gross-To-Net Will be Less Than 65% Beginning January 2023 - - Returned $10M in Capital to Shareholders
Read more →COLLCollegium to Report Third Quarter 2022 Financial Results on November 3, 2022
STOUGHTON, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that it will report third quarter 2022 financial results after the market closes on Thursday, November 3, 20
Read more →COLLCollegium Announces 11 Poster Presentations at PAINWeek 2022 National Conference
STOUGHTON, Mass., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that 11 poster presentations highlighting data regarding its product portfolio will be presented at the Annu
Read more →COLLCollegium Reports Second Quarter 2022 Financial Results - Generated Record Net Revenue of $123.5 Million - - BDSI Integration Complete; On Track to Exceed Targeted Run Rate Synergies of at Least $75 Million - - Raises Fu
Collegium Reports Second Quarter 2022 Financial Results - Generated Record Net Revenue of $123.5 Million - - BDSI Integration Complete; On Track to Exceed Targeted Run Rate Synergies of at Least $75 Million - - Raises Full Year Adjusted EBITDA Guidance - - Conference Call Sch
Read more →COLLCollegium to Report Second Quarter 2022 Financial Results on August 4, 2022
STOUGHTON, Mass., July 21, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that it will report second quarter 2022 financial results after the market closes on Thursday, August 4, 202
Read more →COLLCollegium to Participate in H.C. Wainwright Global Investment Conference
STOUGHTON, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that management will present at the H.C. Wainwright Global Investment Conference being held at the Fontainebl
Read more →COLLCollegium Reports First Quarter 2022 Financial Results - Generated Net Revenue of $83.8 Million - - Completed BDSI Acquisition; On Track to Exceed Targeted Run Rate Synergies of at Least $75 Million - - Resolved All Opio
Collegium Reports First Quarter 2022 Financial Results - Generated Net Revenue of $83.8 Million - - Completed BDSI Acquisition; On Track to Exceed Targeted Run Rate Synergies of at Least $75 Million - - Resolved All Opioid-Industry Litigation - - Reaffirms 2022 Financial Guid
Read more →COLL▼ -5.2%on this news
Collegium to Host Conference Call to Discuss First Quarter 2022 Financial Results
STOUGHTON, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Tuesday, May 10, 2022 at 4:30 p.m. E
Read more →COLLApril 2022 | Nasdaq: COLL Corporate Presentation Investor Presentation Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act o
Reconciliation of GAAP Net Income to Adjusted EBITDA (in thousands) (unaudited) GAAP net (loss) income $ (25,034) $ 6,958 $ 71,517 $ 26,752 Adjustments: Interest expense 4,757 7,737 21,014 28,882 Interest income (3) (3) (12) (232) Provision for (benefit from) income taxes (13,842
Read more →COLLCollegium to Participate in Upcoming Needham Healthcare Conference
STOUGHTON, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that management will participate in the following investor conference: 21st Annual Needham Virtual Healthc
Read more →COLLCollegium Appoints Neil McFarlane to its Board of Directors
STOUGHTON, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced the appointment of Neil F. McFarlane to its Board of Directors, effective April 6, 2022. “Collegium is del
Read more →COLLCollegium Provides 2022 Financial Guidance - Total Product Revenues Expected in the Range of $450.0 million to $465.0 million - - Adjusted Operating Expenses Expected in the Range of $130.0 million to $140.0 million - -
Collegium Provides 2022 Financial Guidance - Total Product Revenues Expected in the Range of $450.0 million to $465.0 million - - Adjusted Operating Expenses Expected in the Range of $130.0 million to $140.0 million - - Adjusted EBITDA Expected in the Range of $235.0 millio
Read more →COLLCollegium Provides 2022 Financial Guidance
– Total Product Revenues Expected in the Range of $450.0 million to $465.0 million – – Adjusted Operating Expenses Expected in the Range of $130.0 million to $140.0 million – – Adjusted EBITDA Expected in the Range of $235.0 million to $250.0 million – STOUGHTON, Mass., April
Read more →COLLCollegium Announces Master Settlement Agreement Resolving Pending Opioid-Related Litigation
STOUGHTON, Mass., March 30, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the execution of a Master Settlement Agreement resolving all 27 pending opioid-related lawsuits brought against the Company by cities, counties, and other subdivisio
Read more →COLLCollegium Completes the Acquisition of
Collegium Completes the Acquisition of BDSI STOUGHTON, Mass., March 22, 2022 -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) ("Collegium") today announced that it has completed the acquisition of BioDelivery Sciences International Inc. (Nasdaq: BDSI) ("BDSI"). "This acquisit
Read more →COLLCollegium Completes the Acquisition of BDSI
STOUGHTON, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) (“Collegium”) today announced that it has completed the acquisition of BioDelivery Sciences International Inc. (Nasdaq: BDSI) (“BDSI”). “This acquisition is a major step forward in
Read more →COLLCollegium Reports Fourth Quarter and Full-Year 2021 Financial Results - BDSI Acquisition Expected to Close Late Q1 2022 - - 2022 Revenue Guidance of $315-$330 Million, Growth Driven by Xtampza ER - - Full-Year Net Income
Collegium Reports Fourth Quarter and Full-Year 2021 Financial Results - BDSI Acquisition Expected to Close Late Q1 2022 - - 2022 Revenue Guidance of $315-$330 Million, Growth Driven by Xtampza ER - - Full-Year Net Income of $71.5 Million and Full-Year Adjusted EBITDA of $118.3
Read more →COLL▲ +13.1%on this news· ran to +25% by day 3
Collegium to Acquire BioDelivery Sciences Broadening Pain Portfolio - Expected to be Immediately and Highly Accretive Driven by Identified Annual Synergies of at Least $75 Million - - Will Diversify Revenue Growth and Ac
Collegium to Acquire BioDelivery Sciences Broadening - Expected to be Immediately and Highly Accretive Driven by Identified Annual Synergies of at Least $75 Million - - Will Diversify Revenue Growth and Accelerate Cash Flow Generation - Addition of BELBUCA Provides a Second
Read more →COLL▲ +13.1%on this news· ran to +25% by day 3
Collegium to Acquire BioDelivery Sciences in an All-Cash Deal
Transaction is valued at $5.60 per share representing a total equity value of $604 million Represents a 54% premium to BDSI stock’s closing price of $3.64 on February 11, 2022 and a 65% premium to the 30 trading days volume weighted average price of $3.40 Transaction expected t
Read more →COLLCollegium to Host Conference Call to Discuss Fourth Quarter and Full-Year 2021 Financial Results
STOUGHTON, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that the Company will host a conference call and live audio webcast on Thursday, February 24, 2022, at 4:30 p.m. Eastern Time. The Company will discuss its fourth qua
Read more →COLLCollegium Announces Settlement Framework to Resolve Pending Opioid-Related Litigation
Collegium Announces Settlement Framework to Resolve Pending Opioid-Related Litigation Mass., December 28, 2021 -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced the
Read more →COLLCollegium Ranks as a Top Place to Work for 2021 by The Boston Globe
STOUGHTON, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that it has been named one of the Top Places to Work in Massachusett
Read more →COLLCollegium to Participate in Upcoming Conferences
STOUGHTON, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that management will participate in the following investor conferenc
Read more →COLLCollegium Reports Third Quarter Fiscal 2021 Results - Board of Directors Has Authorized $25 Million Accelerated Share Repurchase Program - - Net Income of $8.0 Million and Adjusted EBITDA of $37.3 Million - - Full-Year 2
Collegium Reports Third Quarter Fiscal 2021 Results - Board of Directors Has Authorized $25 Million Accelerated Share Repurchase Program - - Net Income of $8.0 Million and Adjusted EBITDA of $37.3 Million - - Full-Year 2021 Guidance Updated - - Conference Call Scheduled for T
Read more →COLLCollegium to Host Conference Call to Discuss Third Quarter 2021 Financial Results and Provide Corporate Update
STOUGHTON, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, announced today that the Company will host a conference call and live webcast on Thu
Read more →COLLCollegium Announces Four Posters Presented at PAINWeek 2021 National Conference
STOUGHTON, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that four poster presentations highlighting data regarding its prod
Read more →COLL▲ +14.5%on this news
Collegium Announces $100 Million Share Repurchase Program
STOUGHTON, Mass., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that its Board of Directors has authorized the repurchase of up to $
Read more →COLLCollegium Reports Strong Q2 Results with Cash Balance Growing to Over $200 Million - Xtampza ER Market Share Grew to 31.5% of the Oxycodone Extended-Release Market in June 2021 - - Net Income of $72.8 Million and Adjuste
Collegium Reports Strong Q2 Results with Cash Balance Growing to Over $200 Million - Xtampza ER Market Share Grew to 31.5% of the Oxycodone Extended-Release Market in June 2021 - - Net Income of $72.8 Million and Adjusted EBITDA of $40.1 Million - - Full-Year 2021 Product Reve
Read more →COLLCollegium to Host Conference Call to Discuss Second Quarter 2021 Financial Results and Provide Corporate Update
STOUGHTON, Mass., July 21, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live webcast on Thursday, August 5, 2021, at 4:30 p.m. Eastern Time. The Company will discuss its financial results a
Read more →COLLCollegium Announces Publication of Real-World Data in Journal of Pain Research
STOUGHTON, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced a publication titled, “Nonmedical Use of Xtampza® ER and Other Oxyco
Read more →COLLCollegium Pharmaceutical, Inc. Corporate Overview June 2021 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We
These items are uncertain and depend on various factors that could have a material impact on GAAP net income (loss) for the guidance period. 2021: Focused on Growth & Value Creation Deliver on our missionICreate value for shareholders OUR STRATEGY Maximize the value of our differ
Read more →COLLCollegium to Participate in Upcoming Investor Conference
STOUGHTON, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that management will participate in the following investor conference
Read more →COLLCollegium Reports Record Quarterly Revenue of $87.7 Million - Net Income of $15.7 Million and Adjusted EBITDA of $45.3 Million in the First Quarter of 2021 - - Nucynta Franchise and Adjusted EBITDA 2021 Guidance Range Ra
Collegium Reports Record Quarterly Revenue of $87.7 Million - Net Income of $15.7 Million and Adjusted EBITDA of $45.3 Million in the First Quarter of 2021 - - Nucynta Franchise and Adjusted EBITDA 2021 Guidance Range Raised - - Colleen Tupper Appointed as Next CFO; Paul Bran
Read more →COLLCollegium to Host Conference Call to Discuss First Quarter 2021 Financial Results and Provide Corporate Update
STOUGHTON, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, May 6, 2021 at 4:30 p.m. Eastern Time. The Company will discuss its financial result
Read more →COLLCollegium Reports Record Full-Year 2020 Revenue of $310.0 Million - 2020 First Full-Year of Profitability, Driven by Xtampza ER Revenue Growth and the Nucynta Acquisition - - Collegium Reiterates Previously Issued 2021 G
Collegium Reports Record Full-Year 2020 Revenue of $310.0 Million - 2020 First Full-Year of Profitability, Driven by Xtampza ER Revenue Growth and the Nucynta Acquisition - - Collegium Reiterates Previously Issued 2021 Guidance - - Conference Call Scheduled for Today at 4:30 p
Read more →COLLCollegium to Host Conference Call to Discuss Fourth Quarter 2020 Financial Results and Provide Corporate Update
STOUGHTON, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, February 25, 2021 at 4:30 p.m. Eastern Time. The Company will discuss its financial r
Read more →COLLCollegium Provides 2021 Financial Guidance - Xtampza ER Revenues Expected in the Range of $155.0 million to $165.0 million - - Nucynta Franchise Revenues Expected in the Range of $175.0 million to $185.0 million - - Adju
Collegium Provides 2021 Financial Guidance - Xtampza ER Revenues Expected in the Range of $155.0 million to $165.0 million - Revenues Expected in the Range of $175.0 million to $185.0 million - - Adjusted EBITDA Expected in the Range of $160.0 million to $170.0 million - ST
Read more →COLLCollegium Provides 2021 Financial Guidance
– Xtampza® ER Revenues Expected in the Range of $155.0 million to $165.0 million – – Nucynta® Franchise Revenues Expected in the Range of $175.0 million to $185.0 million – – Adjusted EBITDA Expected in the Range of $160.0 million to $170.0 million – STOUGHTON, Mass., Jan. 06,
Read more →COLLCollegium Reports Net Income of $11.3 Million in the Third Quarter of 2020 - Strengthened Formulary Access for Xtampza ER, Including Exclusive National Medicare Part D Win - - Generated $34.2 Million in Cash Flow from Op
Collegium Reports Net Income of $11.3 Million in the Third Quarter of 2020 - Strengthened Formulary Access for Xtampza ER, Including Exclusive National Medicare Part D Win - - Generated $34.2 Million in Cash Flow from Operations - - Adjusted EBITDA of $41.8 Million - - Confer
Read more →COLLCollegium Announces Publication of “Postmarketing Analysis of Misuse, Abuse, and Diversion of Xtampza ER” in Pain Medicine
STOUGHTON, Mass., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced a publication titled, “Postmarketing Analysis of Misuse, Abuse and D
Read more →COLLCollegium to Host Conference Call to Discuss Third Quarter 2020 Financial Results and Provide Corporate Update
STOUGHTON, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, November 5, 2020 at 4:30 p.m. Eastern Time. The Company will discuss its financial re
Read more →COLLCollegium Announces Settlement with Teva Resolving Xtampza ER Patent Litigation
Collegium Announces Settlement with Teva Resolving Xtampza ER Patent Litigation STOUGHTON, Mass., September 30, 2020 -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announ
Read more →COLLCollegium Appoints Rita Balice-Gordon to its Board of Directors
Collegium Appoints Rita Balice-Gordon to its Board of Directors STOUGHTON, Mass., September 25, 2020 -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced the appointm
Read more →COLLCollegium Announces Five Posters Presented at PAINWeek 2020 National Conference
STOUGHTON, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that five poster presentations highlighting data regarding its prod
Read more →COLLCollegium Announces Scientific Presentations at PAINWeek 2020 National Conference
STOUGHTON, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that five poster presentations highlighting data regarding its prod
Read more →COLLCollegium Reports Net Income of $8.1 Million in the Second Quarter of 2020 - Non-GAAP Net Income of $33.2 Million in the Second Quarter of 2020 - - Generated $43.9 Million in Cash from Operating Activities in the Second
Collegium Reports Net Income of $8.1 Million in the Second Quarter of 2020 - Non-GAAP Net Income of $33.2 Million in the Second Quarter of 2020 - - Generated $43.9 Million in Cash from Operating Activities in the Second Quarter of 2020 - - Xtampza ER Net Revenue Increased 29%
Read more →COLLCollegium to Host Conference Call to Discuss Second Quarter 2020 Financial Results and Provide Corporate Update
STOUGHTON, Mass., July 21, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, August 5, 2020 at 4:30 p.m. Eastern Time. The Company will discuss its financial res
Read more →COLLCollegium Pharmaceutical Named one of Boston Business Journal’s 2020 Best Places to Work
STOUGHTON, Mass., June 17, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that it has been named one of Boston Business Journal’s 2020 Best Pl
Read more →COLLCollegium Reports First Quarter 2020 Profitability – Achieves GAAP Profitability with $0.5 Million in Net Income in the First Quarter of 2020 – – Non-GAAP Net Income of $31.2 Million in the First Qua
Collegium Reports First Quarter 2020 Profitability Achieves GAAP Profitability with $0.5 Million in Net Income in the First Quarter of 2020 Non-GAAP Net Income of $31.2 Million in the First Quarter of 2020 Xtampza ER Prescriptions Grew 30% Over the First Quarter of 2019 Colle
Read more →COLLCollegium to Host Conference Call to Discuss First Quarter 2020 Financial Results and Provide Corporate Update
STOUGHTON, Mass., April 23, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, May 7, 2020 at 4:30 p.m. Eastern Time. The Company will discuss its financial result
Read more →COLLCollegium Reports Full-Year 2019 Revenue of $296.7 Million - 2019 Revenue Growth of 6%, Driven by Xtampza ER revenue growth of 51% - - Xtampza ER Prescriptions Grew 49% in 2019 - - Collegium Guides to Profitability in 20
Reports Full-Year 2019 Revenue of $296.7 Million 2019 Revenue Growth of 6%, Driven by Xtampza ER revenue growth of 51% - Xtampza ER Prescriptions Grew 49% in 2019 - Collegium Guides to Profitability in 2020 - Conference Call Scheduled for Today at 4:30 p.m. ET - STOUGHTON, M
Read more →COLLCollegium to Host Conference Call to Discuss Fourth Quarter and Full-Year 2019 Financial Results and Provide Corporate Update
STOUGHTON, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, confirmed today the details of the year-end earnings call, previously announced on F
Read more →COLLCollegium Announces Closing of the Nucynta Franchise Acquisition - Collegium Announces Closing of Convertible Senior Notes Offering and Exercise in Full of Over-Allotment Option - - Collegium will Host Conference Call to
Collegium Announces Closing of the Nucynta Franchise Acquisition - Collegium Announces Closing of Convertible Senior Notes Offering and Exercise in Full of Over-Allotment Option - - Collegium will Host Conference Call to Discuss Fourth Quarter 2019 Financial Results and Prov
Read more →COLLCollegium Pharmaceutical, Inc. Prices $125.0 Million Convertible Senior Notes Offering
STOUGHTON, Mass., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ: COLL) today announced the pricing of its offering of $125,000,000 aggregate principal amount of 2.625% convertible senior notes due 2026 (the “notes”) in a public offering registered under
Read more →COLLCollegium to Acquire U.S. Rights to Nucynta Franchise - Financially Transformative Acquisition - - Expected to Significantly Grow Net Income, EBITDA and Operating Cash Flows - - Structure of the Financing Allows for Rapi
Collegium to Acquire U.S. Rights to Nucynta - Financially Transformative Acquisition - Expected to Significantly Grow Net Income, EBITDA and Operating Cash Flows - - Structure of the Financing Allows for Rapid De-Leveraging - - Provides Financial Flexibility to Pursue Futu
Read more →COLLCollegium Provides 2020 Financial Guidance - Xtampza ER Revenues Expected in the Range of $150.0 Million to $160.0 Million for 2020
Collegium Provides 2020 Financial Guidance - Xtampza ER Revenues Expected in the Range of $150.0 Million to $160.0 Million for 2020 - STOUGHTON, Mass., Jan. 7, 2020 -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the lea
Read more →COLLCollegium Provides 2020 Financial Guidance
– Xtampza® ER Revenues Expected in the Range of $150.0 Million to $160.0 Million for 2020 – STOUGHTON, Mass., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain man
Read more →COLLCollegium Reports Third Quarter 2019 Financial Results New Exclusive Formulary Wins Announced for Xtampza ER Effective
Collegium Reports Third Quarter 2019 Financial Results New Exclusive Formulary Wins Announced for Xtampza ER Effective January 1, 2020 Covering More than 35 Million Lives Xtampza ER Net Product Revenues Were $26.5 Million in the Third Quarter of 2019, a 56% Increase Over the Th
Read more →COLLCollegium to Host Conference Call to Discuss Third Quarter 2019 Financial Results and Provide Corporate Update
STOUGHTON, Mass., Oct. 23, 2019 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, November 6, 2019 at 4:30 p.m. Eastern Time. The Company will discuss its financial r
Read more →COLLCollegium Announces Scientific Presentations at PAINWeek 2019 National Conference
STOUGHTON, Mass., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that four poster presentations relating to rates of abuse and divers
Read more →COLLCollegium Reports Second Quarter 2019 Financial Results Xtampza ER Net Product Revenues Were $26.0 Million in the Second Quarter of 2019, a 44% Increase Over the Second Quarter of 2018 Cash and Cash Equivalents Increased
Collegium Reports Second Quarter 2019 Financial Results Xtampza ER Net Product Revenues Were $26.0 Million in the Second Quarter of 2019, a 44% Increase Over the Second Quarter of 2018 Cash and Cash Equivalents Increased to $148.7 Million as of June 30, 2019, From $134.9 Millio
Read more →COLLCollegium to Host Conference Call to Discuss Second Quarter 2019 Financial Results and Provide Corporate Update
STOUGHTON, Mass., July 24, 2019 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, August 7, 2019 at 4:30 p.m. Eastern Time. The Company will discuss its financial res
Read more →COLLCollegium to Present at Upcoming Investor Conferences
STOUGHTON, Mass., May 29, 2019 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that management will present at the following investor conferences in
Read more →COLLCollegium Reports First Quarter 2019 Financial Results Xtampza ER Net Product Revenues of $25.1 million in the First Quarter of 2019, a 59% increase over the First Quarter of 2018 and a 36% increase on a Consecutive-Quar
Collegium Reports First Quarter 2019 Financial Results Xtampza ER Net Product Revenues of $25.1 million in the First Quarter of 2019, a 59% increase over the First Quarter of 2018 and a 36% increase on a Consecutive-Quarter Basis Net loss of $9.7 million in the First Quarter of
Read more →COLLCollegium to Host Conference Call to Discuss First Quarter 2019 Financial Results and Provide Corporate Update
STOUGHTON, Mass., April 24, 2019 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, May 8, 2019 at 4:30 p.m. Eastern Time. The Company will discuss its financial resu
Read more →COLLCollegium Appoints Richard Malamut, M.D., as Chief Medical Officer
STOUGHTON, Mass., April 02, 2019 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced the appointment of Richard Malamut, M.D., as the company’s first Ch
Read more →COLLCollegium Reports Fourth-Quarter and Full-Year 2018 Financial Results Xtampza ER Prescriptions Grew 233% in 2018 Net Revenue Increased to $73.4 Million for Fourth Quarter 2018 and $280.4 Million for the Full Year Cash an
Collegium Reports Fourth-Quarter and Full-Year 2018 Financial Results Xtampza ER Prescriptions Grew 233% in 2018 Net Revenue Increased to $73.4 Million for Fourth Quarter 2018 and $280.4 Million for the Full Year Cash and Cash Equivalents were $146.6 million as of December 31,
Read more →COLLCollegium to Host Conference Call to Discuss Fourth Quarter 2018 Financial Results and Provide Corporate Update
STOUGHTON, Mass., Feb. 13, 2019 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, February 27, 2019 at 4:30 p.m. Eastern Time. The Company will discuss its financial
Read more →COLLCollegium Provides Full-Year 2019 Financial Guidance Xtampza ER Revenue Expected in the Range of $95 Million to $105 Million Nucynta Franchise Revenue Expected in the Range of $200 Million to $210 Million Total Operating
Collegium Provides Full-Year 2019 Financial Guidance Xtampza ER Revenue Expected in the Range of $95 Million to $105 Million Nucynta Franchise Revenue Expected in the Range of $200 Million to $210 Million Total Operating Expenses Expected in the Range of $125 Million to $135 M
Read more →COLLCollegium Reports Third Quarter Financial Results Net Product Revenues were $70.2 million for the third quarter of 2018, a 487% increase versus third quarter of 2017 Thirteen exclusive ER oxycodone formulary wins announc
Collegium Reports Third Quarter Financial Results Net Product Revenues were $70.2 million for the third quarter of 2018, a 487% increase versus third quarter of 2017 Thirteen exclusive ER oxycodone formulary wins announced for Xtampza ER effective January 1, 2019 Cash increase
Read more →COLLCollegium Reports Third Quarter Financial Results
Net Product Revenues were $70.2 million for the third quarter of 2018, a 487% increase versus third quarter of 2017 Thirteen exclusive ER oxycodone formulary wins announced for Xtampza ER effective January 1, 2019 Cash increased by $6.0 million, to $139.8 million as of Septembe
Read more →COLLCollegium Announces Publication of Data on Oral Abuse Potential of Xtampza ER
STOUGHTON, Mass., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the publication of “Evaluation of the oral human abuse potential of Oxycodone DETERx® formulation (Xtampza® ER),” in the peer-reviewed medical journal, Journal of Opi
Read more →COLLCollegium to Host Conference Call to Discuss Third Quarter 2018 Financial Results and Provide Corporate Update
STOUGHTON, Mass., Oct. 17, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, November 8, 2018 at 4:30 p.m. Eastern Time. The Company will discuss its financial r
Read more →COLLCollegium to Present at Upcoming Investor Conference
STOUGHTON, Mass., Sept. 28, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that management will present at the following investor conference in October: The Cantor Global Healthcare Conference on Tuesday, October 2nd at 2:50 p.m. ET in New
Read more →COLLCollegium Announces Scientific Presentations at PAINWeek 2018 Meeting
STOUGHTON, Mass., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it has supported the following poster presentations on tapentadol (Nucynta® and Nucynta® ER), at PAINWeek 2018 on September 6th in Las Vegas. The following post
Read more →COLLCollegium Reports Second Quarter Financial Results and Provides Corporate Update Net revenue $73.1 million for the second quarter of 2018, 1,952% increase vs second quarter 2017, 15% vs first quarter 2018 Xtampza ER pres
Collegium Reports Second Quarter Financial Results and Provides Corporate Update Net revenue $73.1 million for the second quarter of 2018, 1,952% increase vs second quarter 2017, 15% vs first quarter 2018 Xtampza ER prescriptions grew by 23% in the second quarter of 2018 Cash
Read more →COLLCollegium to Host Conference Call to Discuss Second Quarter 2018 Financial Results and Provide Corporate Update
CANTON, Mass., July 20, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, August 8, 2018 at 4:30 p.m. Eastern Time. The Company will discuss its financial result
Read more →COLLCollegium Announces Promotion of Scott Dreyer to CCO
CANTON, Mass., July 10, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the promotion of Scott Dreyer to the position of Executive Vice President and Chief Commercial Officer, effective July 10, 2018. Mr. Dreyer brings over 25 years of commer
Read more →COLLCollegium Announces CEO Succession Joseph Ciaffoni Promoted to CEO and Appointed to Board Michael Heffernan Continues to serve as Chairman of the Board
Collegium Announces CEO Succession Joseph Ciaffoni Promoted to CEO and Appointed to Board Michael Heffernan Continues to serve as Chairman of the Board CANTON, Mass., June 4, 2018 (GLOBE NEWSWIRE) Collegium Pharmaceutical, Inc. (NASDAQ: COLL) today announced that Joseph Ciaffo
Read more →COLLCollegium Announces CEO Succession
Joseph Ciaffoni Promoted to CEO and Appointed to Board Michael Heffernan Continues to serve as Chairman of the Board CANTON, Mass., June 04, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that Joseph Ciaffoni, Executive Vice President and
Read more →COLLCollegium Reports First Quarter Financial Results and Provides Corporate Update Net revenue of $63.7 million, compared to $10.8 million in Q4 2017 Xtampza ER prescriptions grew by 72% in the first quarter Integration of
Collegium Reports First Quarter Financial Results and Provides Corporate Update Net revenue of $63.7 million, compared to $10.8 million in Q4 2017 Xtampza ER prescriptions grew by 72% in the first quarter Integration of the Nucynta franchise into the commercial organization C
Read more →COLLCollegium to Present at the Deutsche Bank Health Care Conference
CANTON, Mass., May 02, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the Deutsche Bank 43rd Annual Health Care Conference on Tuesday, May 8, 2018 at 12:50 p.m. ET at the Intercontinental Hotel Boston. About
Read more →COLLCollegium to Host Conference Call to Discuss First Quarter 2018 Financial Results and Provide Corporate Update
CANTON, Mass., April 20, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, May 9, 2018 at 4:30 p.m. Eastern Time. The Company will discuss its financial results
Read more →COLLCollegium to Present at the H.C. Wainwright Global Life Sciences Conference
CANTON, Mass., April 04, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the H.C. Wainwright Global Life Sciences Conference on Tuesday, April 10, 2018 at 11:55 a.m. CET at Le Meridien Beach Plaza Hotel in Mont
Read more →COLLCollegium Announces the Appointment of Shirley Kuhlmann as General Counsel
CANTON, Mass., March 19, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the appointment of Shirley Kuhlmann to the newly created position of Executive Vice President and General Counsel and Secretary, effective March 16, 2018. Ms. Kuhlmann w
Read more →COLLCollegium Reports Fourth Quarter Financial Results and Provides Corporate Update Xtampza ER prescriptions grew by 37% in the fourth quarter FDA Approval of sNDA, including Comparative OxyContin Data in label Expanded pro
Collegium Reports Fourth Quarter Financial Results and Provides Corporate Update Xtampza ER prescriptions grew by 37% in the fourth quarter FDA Approval of sNDA, including Comparative OxyContin Data in label Expanded product portfolio by licensing rights to commercialize Nucyn
Read more →COLLCollegium to Host Conference Call to Discuss Fourth Quarter 2017 Financial Results and Provide Corporate Update
CANTON, Mass., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, March 7, 2018 at 4:30 p.m. Eastern Time. The Company will discuss its financial results
Read more →COLLCollegium Announces Closing of Agreement to License Rights to Commercialize Nucynta Franchise Establishes Collegium as a leader in responsible pain management Broadens portfolio of meaningfully differentiated products Im
Collegium Announces Closing of Agreement to License Rights to Commercialize Nucynta Franchise Establishes Collegium as a leader in responsible pain management Broadens portfolio of meaningfully differentiated products Immediately accretive, accelerates time to profitability L
Read more →COLLCollegium to Participate in the Guggenheim Securities 5th Annual Boston Healthcare Conference
CANTON, Mass., Dec. 12, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will be hosting investor meetings at the Guggenheim Securities 5th Annual Boston Healthcare Conference on Wednesday, December 13, 2017 at The InterContine
Read more →COLLCollegium to License Rights to Commercialize Nucynta Franchise Establishes Collegium as a leader in responsible pain management Broadens portfolio of meaningfully differentiated products Immediately accretive, accelerate
Collegium to License Rights to Commercialize Nucynta Franchise Establishes Collegium as a leader in responsible pain management Broadens portfolio of meaningfully differentiated products Immediately accretive, accelerates time to profitability Leverages Collegium s existing c
Read more →COLLCollegium to Present at the 29th Annual Piper Jaffray Healthcare Conference
CANTON, Mass., Nov. 22, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that senior management will participate in a fireside chat at the 29th Annual Piper Jaffray Healthcare Conference at 2:30pm ET on Tuesday, November 28, 2017 in New York C
Read more →COLLCollegium Reports Third Quarter Financial Results and Provides Corporate Update Xtampza ER prescriptions grow by 49% in the third quarter FDA Approval of sNDA, including Comparative OxyContin Data Strong balance sheet pr
Collegium Reports Third Quarter Financial Results and Provides Corporate Update Xtampza ER prescriptions grow by 49% in the third quarter FDA Approval of sNDA, including Comparative OxyContin Data Strong balance sheet provides cash runway into mid-2019 Conference call schedul
Read more →COLLCollegium Receives FDA Approval for sNDA for Xtampza ER
CANTON, Mass., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the U.S. Food and Drug Administration (FDA) approved its Supplemental New Drug Application (sNDA) to enhance the label for Xtampza® ER (oxycodone extended-release),
Read more →COLLCollegium Notified that the FDA Will Not Meet PDUFA Goal Date for sNDA for Xtampza ER
CANTON, Mass., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the U.S. Food and Drug Administration (FDA) will not meet the prescription drug user fee act (PDUFA) date for its Supplemental New Drug Application (sNDA) to enhanc
Read more →COLLCollegium to Host Conference Call to Discuss Third Quarter 2017 Financial Results and Provide Corporate Update
CANTON, Mass., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, November 8, 2017 at 4:30 p.m. Eastern Time. The Company will discuss its financial resul
Read more →COLLCollegium Announces Scientific Presentations at PAINWeek 2017 Meeting
CANTON, Mass., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it will present data on Xtampza® ER, an extended-release oral formulation of oxycodone with abuse-deterrent properties, at PAINWeek 2017 on September 7th in Las Veg
Read more →COLLCollegium Reports Second Quarter Financial Results and Provides Corporate Update Collegium strengthens leadership team with key additions to executive team and Board of Directors Xtampza ER prescriptions grow by 34% in t
Collegium Reports Second Quarter Financial Results and Provides Corporate Update Collegium strengthens leadership team with key additions to executive team and Board of Directors Xtampza ER prescriptions grow by 34% in the second quarter Xtampza ER Notice of Allowance granted
Read more →COLLCollegium to Host Conference Call to Discuss Second Quarter 2017 Financial Results and Provide Corporate Update
CANTON, Mass., July 18, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, August 9, 2017 at 4:30 p.m. Eastern Time. The Company will discuss its financial result
Read more →COLLCollegium Announces Scientific Presentations at the 2017 International Conference on Opioids
CANTON, Mass., June 08, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it will present data on Xtampza® ER, an extended-release oral formulation of oxycodone with abuse-deterrent properties, at the 2017 International Conference on Opioi
Read more →COLLCollegium Announces Additional Managed Care Coverage for Xtampza ER for Medicare Part D Patients
CANTON, Mass., June 01, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that one of the largest managed care organizations with approximately 8 million Medicare Part D lives has added Xtampza® ER to its Medicare Part D formularies. Effective
Read more →COLLCollegium Announces the Appointment of Joseph Ciaffoni as Chief Operating Officer
Collegium Announces the Appointment of Joseph Ciaffoni as Chief Operating Officer CANTON, Mass., May 30, 2017 (GLOBE NEWSWIRE) Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the appointment of Joseph Ciaffoni to the newly created position of Executive Vice Preside
Read more →COLLCollegium Reports First Quarter Financial Results and Provides Corporate Update Xtampza ER prescribed by more than 3,000 physicians since commercial launch Xtampza ER Notice of Allowance granted and, once issued, will ex
Collegium Reports First Quarter Financial Results and Provides Xtampza ER prescribed by more than 3,000 physicians since commercial launch Xtampza ER Notice of Allowance granted and, once issued, will extend patent protection until 2030 Well capitalized with $129.6 million in
Read more →COLLCollegium to Host Conference Call to Discuss First Quarter 2017 Financial Results and Provide Corporate Update
CANTON, Mass., May 03, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, May 10, 2017 at 4:30 p.m. Eastern Time. The Company will discuss its financial results an
Read more →COLLCollegium to Present at the 42nd Annual Deutsche Bank Healthcare Conference
CANTON, Mass., April 20, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it will present at the 42nd Annual Deutsche Bank Healthcare Conference in Boston. The presentation will take place at 10:40 a.m. ET on Wednesday, May 3, 2017 at the
Read more →COLLCollegium Announces Appointment of Steven Passik, PhD, as Vice President, Scientific Affairs, Education and Policy
CANTON, Mass., April 04, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced it has appointed Steven Passik, PhD, as Vice President of Scientific Affairs, Education and Policy, effective, April 3, 2017. “We are excited to announce the addition o
Read more →COLLCollegium Announces Expanded Managed Care Coverage for Xtampza ER for Medicare Part D Patients
CANTON, Mass., April 03, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that a large national managed care organization with more than 3 million Medicare Part D lives has added Xtampza® ER to its Medicare Part D formularies. Effective April
Read more →COLLCollegium to Present at the 16th Annual Needham Healthcare Conference
CANTON, Mass., March 28, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it will present at the 16th Annual Needham Healthcare Conference in New York City. The presentation will take place at 10:40 a.m. ET on Wednesday, April 5, 2017 at
Read more →COLLCollegium Announces Scientific Presentation at American Academy of Pain Medicine 2017 Meeting
CANTON, Mass., March 16, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it will present data on Xtampza® ER, an extended-release oral formulation of oxycodone with abuse-deterrent properties, at the 33rd Annual American Academy of Pain
Read more →COLLCollegium Reports Fourth Quarter Financial Results and Provides Corporate Update Xtampza ER prescribed by more than 2,400 physicians since commercial launch ONSOLIS patent issued that extends patent protection until 2027
Collegium Reports Fourth Quarter Financial Results and Provides Corporate Update Xtampza ER prescribed by more than 2,400 physicians since commercial launch ONSOLIS patent issued that extends patent protection until 2027 Well capitalized with $153.2 million in cash and cash eq
Read more →COLLCollegium to Host Conference Call to Discuss 2016 Financial Results and Provide Corporate Update
CANTON, Mass., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, March 9, 2017 at 4:30 p.m. Eastern Time. The Company will discuss its financial results a
Read more →COLLCollegium Announces Positive Topline Results of Human Abuse Potential Clinical Trial Evaluating the Oral Abuse of Xtampza ER
CANTON, Mass., Feb. 01, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced positive topline results from an oral human abuse potential clinical trial, which was designed to evaluate the abuse potential and pharmacokinetics of oral administration
Read more →COLLCollegium Announces the Addition of Xtampza ER to Express Scripts’ Formulary
CANTON, Mass., Dec. 15, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it has finalized its contract with Express Scripts, the largest pharmacy benefits management (PBM) in the United States. Pursuant to the contract, Xtampza ER is cove
Read more →COLLCollegium Announces Underwriters’ Exercise of Option to Purchase Additional Shares
CANTON, Mass., Nov. 29, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced that the underwriters for its public offering of 5,000,000 shares of its common stock at $16.00 per share have exercised in full their option to purchase an additional 750,000
Read more →COLLCollegium Reports Third Quarter Financial Results and Provides Corporate Update Broadened Xtampza ER market access with commitments from large commercial payers Submitted Supplemental New Drug Application to the FDA Subm
Collegium Reports Third Quarter Financial Results and Provides Corporate Update Broadened Xtampza ER market access with commitments from large commercial payers Submitted Supplemental New Drug Application to the FDA Submitted New Drug Submission to Health Canada CANTON, Mass.
Read more →COLLCollegium to Host Conference Call to Discuss Third Quarter 2016 Financial Results and Provide Corporate Update
CANTON, Mass., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, November 10, 2016 at 4:30 p.m. Eastern Time. The Company will discuss its financial resul
Read more →COLLCollegium Prices Public Offering of $80 million of Common Stock
Collegium Prices Public Offering of $80 million of Common Stock CANTON, Mass., Oct. 26, 2016 (GLOBE NEWSWIRE) Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the pricing of its previously announced public offering of 5,000,000 shares of its common stock at a price t
Read more →COLLCollegium Announces Proposed Public Offering of Common Stock
Collegium Announces Proposed Public Offering of Common Stock CANTON, Mass., October 25, 2016 (GLOBE NEWSWIRE) Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares in th
Read more →COLLCollegium Submits Supplemental New Drug Submission to FDA for Xtampza ER
CANTON, Mass., Oct. 05, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food & Drug Administration (FDA) to enhance the label for Xtampza® ER (oxycodone extended-rel
Read more →COLLCollegium Submits New Drug Submission to Health Canada for Xtampza ER, an Analgesic with Abuse-Deterrent Properties for the Treatment of Chronic Pain
CANTON, Mass., Oct. 03, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today the submission of a New Drug Submission (NDS) to Health Canada seeking marketing approval of Xtampza® ER (oxycodone extended-release), an abuse-deterrent, extended-releas
Read more →COLLCollegium to Present at the BioCentury NewsMakers Conference
CANTON, Mass., Sept. 07, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at BioCentury’s 23rd Annual NewsMakers in the Biotech Industry Conference on Friday, September 9, 2016 at 10:30 a.m. Eastern Time. The confe
Read more →COLLCollegium Announces the Launch of OpioidIQ
CANTON, Mass., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) announces the launch of OpioidIQ, an online educational tool to assist physicians and other healthcare providers with more effective pain management (Available at: www.OpioidIQ.com). Th
Read more →COLLCollegium Announces Scientific Presentations at PAINWeek 2016 Meeting
CANTON, Mass., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it will present data on Xtampza® ER, an extended-release oral formulation of oxycodone with abuse-deterrent properties, at PAINWeek 2016 on September 8th in Las Veg
Read more →COLLCollegium Announces Publication of Data on Alternative Modes of Administration of Xtampza ER
CANTON, Mass., Aug. 16, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the publication of “An Abuse-Deterrent, Microsphere-in-Capsule Formulation of Extended-Release Oxycodone: Alternative Modes of Administration to Facilitate Pain Managemen
Read more →COLLCollegium Reports Second Quarter Financial Results and Provides Corporate Update Received FDA approval for Xtampza ER, Company s lead opioid analgesic with abuse-deterrent properties Announced U.S. commercial launch of X
Collegium Reports Second Quarter Financial Results and Provides Corporate Update Received FDA approval for Xtampza ER, Company s lead opioid analgesic with abuse-deterrent properties Announced U.S. commercial launch of Xtampza ER Reported positive results from a clinical study
Read more →COLLCollegium to Host Conference Call to Discuss Second Quarter 2016 Financial Results and Provide Corporate Update
CANTON, Mass., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, August 10, 2016 at 4:30 p.m. Eastern Time. The Company will discuss its financial result
Read more →COLLCollegium Receives European Patent Allowance Covering Xtampza ER
CANTON, Mass., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL), a specialty pharmaceutical company focused on developing and commercializing innovative abuse-deterrent treatments for chronic pain and other diseases, announced that the European Paten
Read more →COLLCollegium to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference
CANTON, Mass., July 06, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference on Tuesday, July 12, 2016 at 8 a.m. Eastern Time. The conference will be held at Le P
Read more →COLLCollegium CEO Michael Heffernan Named EY Entrepreneur of the Year
CANTON, Mass., June 27, 2016 (GLOBE NEWSWIRE) -- EY announced that Collegium’s CEO, Michael Heffernan, received the EY Entrepreneur of the Year® 2016 Award in the Life Sciences and Healthcare category in New England. This year marks the 30th anniversary of the EY Entrepreneur of
Read more →COLLCollegium Announces Positive Topline Results for Hydrocodone DETERx Clinical Study
CANTON, Mass., June 22, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced positive topline results from a clinical study evaluating Hydrocodone DETERx® as a second product candidate using its proprietary DETERx drug delivery technology platform
Read more →COLLCollegium Announces Commercial Launch of Xtampza ER
CANTON, Mass., June 20, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the commercial launch of Xtampza® ER (oxycodone) extended-release (ER) capsules in the United States. Xtampza ER was approved by the U.S. Food and Drug Administration (FD
Read more →COLLCollegium Announces Election of John A. Fallon, M.D. to Board of Directors
CANTON, Mass., June 13, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the election of John A. Fallon, M.D. to the Board of Directors. "John’s broad-based payer, managed care and physician group practice management experience will be of gre
Read more →COLLCollegium Announces Poster Presentations for Xtampza™ ER at the International Conference on Opioids
CANTON, Mass., June 02, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it will present data on the use of Xtampza ER, an extended-release oral formulation of oxycodone with abuse-deterrent properties, at the International Conference on
Read more →COLLCollegium to Present at Jefferies and William Blair Conferences
CANTON, Mass., June 02, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the following investor conferences in June: Jefferies Healthcare Conference, New York, June 7th at 10 a.m. ET William Blair Annual Growt
Read more →COLLCollegium Hosting Investor Day Event on May 25, 2016
CANTON, Mass., May 23, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) will host Investor Day on Wednesday, May 25th at the St. Regis Hotel in New York City (2 East 55th Street). The meeting will commence at 10:00am ET. Parties interested in attending the ev
Read more →COLLCollegium Licenses the U.S. rights to ONSOLIS from BioDelivery Sciences Breakthrough cancer pain product added to the portfolio
Collegium Licenses the U.S. rights to ONSOLIS from BioDelivery Sciences Breakthrough cancer pain product added to the portfolio CANTON, Mass., May 11, 2016 (GLOBE NEWSWIRE) Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today the licensing of the U.S. rights to develop
Read more →COLLCollegium Announces Poster Presentations for Xtampza™ ER at American Pain Society Meeting
CANTON, Mass., May 11, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it will present data on the use of Xtampza™ ER, an extended-release oral formulation of oxycodone with abuse-deterrent properties, in an elderly population at the Ame
Read more →COLLCollegium Reports First Quarter Financial Results and Provides Corporate Update
Collegium Reports First Quarter Financial Results and Provides Corporate Update CANTON, Mass., May 10, 2016 (GLOBE NEWSWIRE) Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today reported its financial results for the first quarter of 2016 and provided a corporate update. The begi
Read more →COLLCollegium Announces Positive Topline Results of Comparative Clinical Trial Evaluating the Effect of Crushing Xtampza™ ER Compared with OxyContin
CANTON, Mass., May 04, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced positive topline results from a comparative clinical trial evaluating the effect of physical manipulation by crushing of Xtampza™ ER (oxycodone extended-release capsules)
Read more →COLLCollegium to Host Conference Call to Discuss First Quarter 2016 Financial Results and Provide Corporate Update
CANTON, Mass., April 27, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Tuesday, May 10, 2016 at 4:30 p.m. Eastern Time. The Company will discuss its financial results an
Read more →COLLCollegium Receives FDA Approval for Xtampza™ ER, an Analgesic with Abuse-Deterrent Properties for the Treatment of Chronic Pain
CANTON, Mass., April 26, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that the U.S. Food and Drug Administration (FDA) approved Xtampza™ ER (oxycodone) extended-release (ER) capsules CII, a twice-daily, oxycodone medication for the managem
Read more →COLLCollegium to Present at the 15th Annual Needham Healthcare Conference
CANTON, Mass., April 08, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that Michael Heffernan, the Company’s CEO, will present at the 15th Annual Needham Healthcare Conference in New York City. The presentation will take place at 1:40 p.m.
Read more →COLLCollegium Announces Publication of Data on the Durability of Pain Relief with Xtampza ER
CANTON, Mass., April 07, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the publication of an analysis of the duration of effect of Xtampza™ ER administered every 12 hours during the Double-blind Maintenance Phase of a multicenter, 12-week c
Read more →COLLCollegium Reports 2015 Financial Results and Provides Corporate Update
Collegium Reports 2015 Financial Results and Provides Corporate Update CANTON, Mass., March 15, 2016 (GLOBE NEWSWIRE) Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today reported its 2015 financial results and provided a corporate update. Over the last few months, we made signi
Read more →COLLCollegium to Host Conference Call to Discuss 2015 Financial Results and Provide Corporate Update
CANTON, Mass., March 10, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Tuesday, March 15, 2016 at 7:30 a.m. ET. The Company will discuss its financial results for 2015 a
Read more →COLLCollegium Announces Publication of Data on the In Vitro Assessment of IV Abuse of Xtampza ER in Journal of Opioid Management
CANTON, Mass., March 03, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the publication of results from a laboratory-based extraction, injection and syringeability study for Xtampza® ER compared to other marketed opioid analgesics in peer-re
Read more →COLLCollegium Announces Favorable Judgment by the District Court of Massachusetts
CANTON, Mass., Feb. 11, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced that the District Court of Massachusetts issued an order for final judgment in favor of Collegium and against plaintiffs Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue
Read more →COLLCollegium Announces Issuance of U.S. Patent Covering DETERx , an Abuse-Deterrent, Extended-Release Technology Platform
CANTON, Mass., Feb. 04, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that U.S. Patent No. 9,248,195 entitled, "Abuse-deterrent Pharmaceutical Compositions of Opioids and Other Drugs" was issued by the U.S. Patent and Trademark Office (USPT
Read more →COLLCollegium Provides Litigation Update
CANTON, Mass., Feb. 02, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today provided an update regarding its ongoing litigation with Purdue Pharma L.P. (“Purdue”). On February 1, 2016, the U.S. Court of Appeals for the Federal Circuit rendered its decision
Read more →COLLCollegium Appoints Ted Schroeder to Board of Directors
Collegium Appoints Ted Schroeder to Board of Directors CANTON, Mass., Jan. 25, 2016 (GLOBE NEWSWIRE) Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the appointment of Ted Schroeder to its board of directors. Mr. Schroeder led specialty pharmaceutical company Cadenc
Read more →COLLCollegium Announces FDA Acceptance of IND Application for Abuse-Deterrent, Hydrocodone DETERx
CANTON, Mass., Jan. 21, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s investigational new drug (IND) application to begin a clinical trial of Hydrocodone DETERx®, a
Read more →COLLCollegium Pharmaceutical, Inc. Prices Public Offering of $55.0 Million of Common Stock
CANTON, Mass., Jan. 08, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the pricing of its public offering of 2,750,000 shares of its common stock at a price to the public of $20.00 per share, before underwriting discounts and commissions. Th
Read more →COLLUNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS ) PURDUE PHARMA L.P., ) THE P.F. LABORATORIES, INC., ) PURDUE PHARMACEUTICALS L.P., ) and RHODES TECHNOLOGIES, ) Civil Action No. ) 15-13099-FDS Plaintiffs, ) ) v. )
UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS ) PURDUE PHARMA L.P., ) THE P.F. LABORATORIES, INC., ) PURDUE PHARMACEUTICALS L.P., ) and RHODES TECHNOLOGIES, ) Civil Action No. ) 15-13099-FDS Plaintiffs, ) ) v. ) ) COLLEGIUM PHARMACEUTICAL, INC, )
Read more →COLLCollegium Announces Publication of Nasal Human Abuse Potential Study in American Academy of Pain Medicine
CANTON, Mass., Dec. 16, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the publication of results from the intranasal human abuse potential of Xtampza™ ER (oxycodone) extended-release capsules. The publication is titled “A Randomized, Double
Read more →COLLCollegium Added to the NASDAQ Biotechnology Index
CANTON, Mass., Dec. 14, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq:NBI). The addition to the NASDAQ Biotechnology Index will become effective prior to marke
Read more →COLLCollegium to Present at the 27th Annual Piper Jaffray Healthcare Conference
CANTON, Mass., Nov. 30, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that Michael Heffernan, the Company's Chairman and CEO, will present at the 27th Annual Piper Jaffray Healthcare Conference in New York City. The presentation will take p
Read more →COLLCollegium Reports Third Quarter Financial Results and Provides Corporate Update
Collegium Reports Third Quarter Financial Results and Provides Corporate Update CANTON, Mass., November 12, 2015 (GLOBE NEWSWIRE) Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today reported its financial results for the third quarter of 2015 and provided a corporate update. Du
Read more →COLLCollegium to Host Conference Call to Discuss Q3 Financial Results and Provide Corporate Update
CANTON, Mass., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, November 12, 2015 at 8:00 a.m. ET. The Company will discuss its financial results for the
Read more →COLLCollegium Announces FDA Tentative Approval for Xtampza(TM) ER, a Novel Abuse-Deterrent Analgesic for Chronic Pain
CANTON, Mass., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that the United States Food and Drug Administration (FDA) has granted tentative approval to the Company's New Drug Application (NDA) for Xtampza ER (oxycodone) extended-re
Read more →COLLCollegium Provides Update on FDA Review of Xtampza(TM) ER, an Abuse-Deterrent Analgesic for the Treatment of Chronic Pain
CANTON, Mass., Oct. 12, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that the U.S. Food and Drug Administration (FDA) has advised Collegium that it will not be able to complete its review of the New Drug Application (NDA) for Xtampza ER (o
Read more →COLLCollegium Announces FDA Advisory Committees Unanimously Recommend Approval of Xtampza ER(TM), an Abuse-Deterrent Analgesic for Chronic Pain
CANTON, Mass., Sept. 11, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee of the U.S. Food and Drug Administration (FDA)
Read more →COLLCollegium to Present Highlights From Xtampza(TM) ER (Oxycodone Extended-Release Capsules) Clinical Development Program at PAINWeek
CANTON, Mass., Sept. 4, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it will present data from the clinical development program for Xtampza ER, an abuse-deterrent, extended-release oral formulation of oxycodone, at PAINWeek 2015, taki
Read more →COLLCollegium Publishes Data From Xtampza(TM) ER Phase 3 Clinical Trial in the Journal PAIN
CANTON, Mass., Aug. 24, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the publication of results from the Phase 3 clinical trial of Xtampza ER (oxycodone extended-release capsules). The study is titled "A phase 3, multi-center, randomized,
Read more →COLLCollegium Reports Second Quarter Financial Results and Provides Corporate Update
Collegium Reports Second Quarter Financial Results and Provides Corporate Update CANTON, Mass., August 12, 2015 (GLOBE NEWSWIRE) Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today reported its financial results for the second quarter of 2015 and provided a corporate update. Mi
Read more →COLLCollegium to Host Conference Call to Discuss Financial Results and Provide Corporate Update
CANTON, Mass., Aug. 7, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, August 13, 2015 at 8:00 a.m. ET. The Company will discuss its financial results for the se
Read more →COLLCollegium Announces FDA Advisory Committee Meeting for Xtampza(TM) ER, an Abuse-Deterrent Analgesic for Chronic Pain
CANTON, Mass., Aug. 7, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee of the U.S. Food and Drug Admi
Read more →COLLCollegium Added to Russell 2000(R), 3000(R) and Global Indexes
CANTON, Mass., July 6, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced that it has been added to the Russell 2000 , Russell 3000 , and Russell Global Indexes as part of Russell Investments' annual reconstitution that took place on June 26, 2015. T
Read more →COLLCollegium Expands Leadership Team With Vice President of Regulatory Affairs and Quality Assurance
CANTON, Mass., July 1, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that John (Jack) Weet, Ph.D., has joined the company as its Vice President of Regulatory Affairs and Quality Assurance. Dr. Weet will oversee Collegium's Regulatory Affair
Read more →COLLCollegium Announces Publication of "Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations With Abuse-Deterrent Properties," in Pain Medicine
CANTON, Mass., June 25, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the publication of a comparative clinical trial titled "Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulati
Read more →COLLCollegium to Present Xtampza ER(TM) Oral Human Abuse Potential Data at the College on Problems of Drug Dependence 77th Annual Meeting
CANTON, Mass., June 15, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the presentation of a scientific poster at the College on Problems of Drug Dependence 77th Annual Meeting, held at the Arizona Biltmore in Phoenix, AZ from June 13 to Jun
Read more →COLLCollegium Announces Issuance of U.S. Patent Covering DETERx(R) - an Abuse-Deterrent, Extended-Release Technology Platform
CANTON, Mass., June 8, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that U.S. Patent No. 9,044,398 was issued by the U.S. Patent and Trademark Office (USPTO) for its patent application entitled, "Abuse-deterrent Pharmaceutical Compositions
Read more →COLLCollegium Expands Commercial Organization With Key Appointments
CANTON, Mass., June 1, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the addition of Barry Duke as Executive Vice President and Chief Commercial Officer. In addition to Mr. Duke, Mary Ogle joined as Vice President of Marketing and Timothy H
Read more →COLLCollegium to Present at the Jefferies 2015 Global Healthcare Conference
CANTON, Mass., May 27, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company's Chairman and CEO, Michael Heffernan, will present at the Jefferies 2015 Healthcare Conference in New York City. The presentation is scheduled for Monday
Read more →COLLCollegium Pharmaceutical Announces Closing of Its Initial Public Offering and Exercise in Full of Option to Purchase Additional Shares
CANTON, Mass., May 12, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today the closing of its initial public offering of 6,670,000 shares of its common stock at a price to the public of $12.00 per share, before underwriting discounts and commissi
Read more →COLLCollegium Pharmaceutical Announces Pricing of Its Initial Public Offering
CANTON, Mass., May 7, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc., (Nasdaq:COLL) today announced the pricing of its initial public offering of 5,800,000 shares of its common stock at a price to the public of $12.00 per share, before underwriting discounts and commissi
Read more →COLLCollegium Pharmaceutical to Present Xtampza ER(TM) Pivotal Phase III Data at the 2015 American Academy of Pain Medicine Annual Meeting
CANTON, Mass., March 17, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. today announced a poster presentation of the Company's completed Phase III clinical trial that evaluated the efficacy and safety of its lead drug candidate, Xtampza ER , an abuse-deterrent, extended-
Read more →COLLCollegium Pharmaceutical Raises $50 Million Financing to Support Commercial Development of Its Lead Abuse-Deterrent Product Candidate
CANTON, Mass., March 10, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative abuse-deterrent treatments for chronic pain and other diseases, today announced that it has raised a
Read more →COLLCollegium Pharmaceutical Announces Notice of Allowance for U.S. Patent Covering DETERx(R), an Abuse-Deterrent, Extended-Release, Technology Platform
CANTON, Mass., Feb. 26, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative abuse-deterrent treatments for chronic pain and other diseases, announced that Application No. 13/551
Read more →COLLCollegium Pharmaceutical Secures FDA Acceptance for Filing of NDA for XTAMPZA ER(TM) (Oxycodone Extended-Release Capsules), an Abuse-Deterrent Analgesic for Chronic Pain
CANTON, Mass., Feb. 17, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative abuse-deterrent treatments for chronic pain and other diseases, announced that the U.S. Food & Drug A
Read more →Competitive Position
How COLL ranks across every disease it competes inCompetitive Position is a premium feature
See how COLL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial